• Explore /
  • Poster
  • / A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.

Abstract Poster

Authors

Meredith McKean

Meredith McKean

Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN

Meredith McKean , Alexander I. Spira , Ezra Rosen , Vivek Subbiah , Victor Moreno , Valentina Gambardella , Maria Vieito , Omar Saavedra , Sophie Cousin , Philippe Alexandre Cassier , Riadh Lobbardi , Oliver Schönborn-Kellenberger , Eunju Hurh , Mary M. Ruisi , Elizabeth Iannotti Buchbinder

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT05668585

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS3163)

DOI

10.1200/JCO.2023.41.16_suppl.TPS3163

Abstract #

TPS3163

Poster Bd #

356a

Abstract Disclosures

Similar Posters

First Author: Jonathan S. Cebon

First Author: Ryan Bruce Corcoran

Poster

2024 ASCO Annual Meeting

Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors.

Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors.

First Author: Mohamed Alaa Gouda

First Author: April K.S. Salama